SCYNEXIS Awarded BARDA Contract Providing Up To $214 Million In Non-Dilutive Funding For The Development Of SCY-247

(MENAFN - GlobeNewsWire - Nasdaq) BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a ...